– UK, London – Avacta Group plc (LON: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Shaun Chilton to its Board as a Non-executive Director, effective immediately.
“Along with my fellow Directors I am delighted to welcome Shaun to the Board of Avacta Group. He brings a wide range of highly relevant commercial experiences from successful healthcare businesses with similar ambitions for growth that we have in Avacta. I know Shaun will positively impact our shared thinking and I’m excited to have him join the company.” said Board Chairman, Dr Eliot Forster.
About Shaun Chilton
Shaun Chilton was most recently CEO of the formerly London-listed Clinigen Group plc, a global pharmaceutical and pharmaceutical services platform business, which he led through a significant growth journey. During his tenure, the company expanded through both an organic and a buy-and-build strategy which included completing several transformational acquisitions. The Company was eventually sold to Triton Partners for a total consideration of c.£1.3 billion in April 2022.
Alongside his role as the CEO of Clinigen, Shaun Chilton was Non-Executive Chairman of C7Health, a disruptive, venture capital-backed medical technology and services business which executed an acquisitive growth journey before successfully being acquired by a strategic buyer in 2022.
Shaun Chilton has held several senior and executive commercial positions over more than 30 years in companies in the pharmaceutical and pharmaceutical services industries. These include Pfizer, Sanofi, Wolters Kluwer Health, and KnowledgePoint360 Group.
Shaun Chilton said: “Avacta Group is building a high-value, global business that is seeking to significantly improve people’s health and well-being. I am excited to leverage my own broad experience of growing healthcare businesses and working with the other members of the Board to help guide Avacta to meet its very significant potential.”
About Avacta Group plc
Avacta Group plc is a life sciences company working to improve people’s health and well-being through innovative oncology drugs and powerful diagnostics. Operating through two divisions, Diagnostics and Therapeutics, the Group’s mission is to provide professionals and consumers with solutions that improve healthcare, fitness, and well-being.
Avacta’s Therapeutics Division, a clinical-stage oncology drug innovator, is building a wholly-owned pipeline of novel Affimer immunotherapies and pre|CISION tumor-targeted chemotherapies. This approach is designed to address the lack of a durable response to current cancer immunotherapies experienced by most patients and reduce the severe systemic toxicities caused by chemotherapies. There are five programs in the pipeline as well as several global research collaborations and licensing partnerships. Avacta’s lead program, AVA6000, is a pre|CISION tumor-targeted form of the established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in patients with locally advanced or metastatic selected solid tumors.
The Affimer platform is an alternative to antibodies that have been designed to address many of the drawbacks of antibodies which, despite their shortcomings, currently dominate the immuno-diagnostics and immuno-therapeutics markets.
The pre|CISION tumor targeting platform can be used to modify chemotherapy to selectively release the active drug in tumor tissue thereby reducing the systemic exposure that causes damage to healthy tissues. pre| CISION-modified chemotherapies are designed to reduce the side effects and improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.
Avacta’s Diagnostics Division develops and supplies a broad range of in-vitro diagnostic solutions. The Division is growing rapidly through an M&A strategy to deliver a global-scale IVD business providing market-leading solutions for healthcare professionals and consumers to inform treatment and monitor health and well-being. In October 2022, Avacta acquired Launch Diagnostics which serves the hospital pathology laboratory market in the UK and Europe. In May 2023, Avacta acquired Coris Bioconcept a Belgium-based lateral flow test developer and manufacturer adding a broad range of marketed professional-use rapid tests into the Diagnostics Division. Avacta Diagnostic’s research and development center in Wetherby, UK uses its proprietary Affimer platform to differentiate immunodiagnostic products to provide marketing-leading performance.
Source: https://www.avacta.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
